# A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

> **NCT03844932** · PHASE2 · TERMINATED · sponsor: **Sublimity Therapeutics Holdco Limited** · enrollment: 235 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** ST-0529

## Key facts

- **NCT ID:** NCT03844932
- **Lead sponsor:** Sublimity Therapeutics Holdco Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-24
- **Primary completion:** 2021-04-14
- **Final completion:** 2021-04-14
- **Target enrollment:** 235 (ACTUAL)
- **Why stopped:** The Sublimity Board of Directors carefully evaluated the IA data: the 9.6% treatment remission difference for 75mg BID vs placebo (due to an increase in placebo response rate) was determined not sufficient to continue to fund the study
- **Last updated:** 2021-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03844932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03844932, "A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03844932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*